CD8A and neoplasm: Bispecific T-cell engagers provide a conduit between the patient’s cytotoxic CD8+ T-cells, commonly through CD3, and the tumour cells resulting in the formation of an immunological synapse and concomitant effector T-cell-mediated killing of the cancer cell [10].